Moschovi Maria, Trimis Georgios, Pergantou Helini, Platokouki Heleni, Vrachnou Eleni, Tzortzatou-Stathopoulou Fotini
Hematology-Oncology Unit, First Department of Pediatrics, University of Athens, Athens, Greece.
J Paediatr Child Health. 2005 Jul;41(7):384-6. doi: 10.1111/j.1440-1754.2005.00641.x.
Two patients, a 4-year-old boy and a 6-year-old girl who had a 2-year and a 3-year history of idiopathic thrombocytopenic purpura, respectively, were referred to our Department. Both patients had frequent haemorrhagic events. They received i.v. immunoglobulin, corticosteroids, cyclosporine, interferon alpha-2b and azathioprine, but no clinical remission was established. The girl also underwent splenectomy. Anti-CD20 antibody was administered to both patients at a dose of 375 mg/m(2) once weekly for 4 weeks. No side-effects were detected. During the 18-month follow-up period the patients received no other drug and remained in clinical remission. The B lymphocytes remained undetectable in peripheral blood for 3 months and they progressively increased during the following 4 months. Rituximab is a novel, quite effective, safe treatment of chronic refractory idiopathic thrombocytopenic purpura in childhood. More studies and follow up of patients for longer periods are necessary.
两名患者，一名4岁男孩和一名6岁女孩，分别有2年和3年特发性血小板减少性紫癜病史，被转诊至我科。两名患者均有频繁出血事件。他们接受了静脉注射免疫球蛋白、皮质类固醇、环孢素、干扰素α-2b和硫唑嘌呤治疗，但未实现临床缓解。该女孩还接受了脾切除术。两名患者均接受了剂量为375 mg/m²的抗CD20抗体治疗，每周一次，共4周。未检测到副作用。在18个月的随访期内，患者未接受其他药物治疗，且一直处于临床缓解状态。外周血中B淋巴细胞在3个月内未被检测到，在接下来的4个月中逐渐增加。利妥昔单抗是治疗儿童慢性难治性特发性血小板减少性紫癜的一种新型、相当有效且安全的治疗方法。需要进行更多研究并对患者进行更长时间的随访。
